OKLAHOMA CITY & AUSTIN, Texas--(BUSINESS WIRE)--Life sciences venture firm Emergent Technologies, Inc. (ETI) announced today that Hyalose, L.L.C., one of ETI’s Oklahoma City-based portfolio companies, received approval from the EDGE Policy Board for a $1.23 million grant to build a center for manufacturing hyaluronic acid (HA) and related glycosaminoglycans (GAG’s) products. The products will be utilized to formulate clinical diagnostic tools and companion therapies. The center will be located in the Presbyterian Health Foundation’s Research Park in Oklahoma City.
